LENZ Therapeutics

LENZ Lead: Approved 2 Biotech Distilled articles ↓

Most recent annual filing: 2026-03-24

Catalyst timeline

VIZZ China decision1Q 2027VIZZ China decision, 1Q 2027, material

Bar width shows how precise the guidance is — a pin is a stated date, a wide band a six-month window. Deeper blue means more of the thesis rides on the event; it is not a view on the stock.

Pipeline (1 active programs)

VIZZ

aceclidine ophthalmic solution · LNZ100

Small Molecule

Presbyopia Approved topical NCT03201562

Discontinued (1)

LNZ101 — Presbyopia · Dropped after Phase 3 CLARITY: LNZ101 (aceclidine + brimonidine) did not demonstrate superiority to LNZ100; company advances LNZ100 (VIZZ) exclusively.

Biotech Distilled coverage (2)

2026-08-12 UPDATE: LENZ Therapeutics (LENZ) - The Refill Data Arrives, The Curve Doesn’t Bend 🔒 Paid
2026-07-14 LENZ Therapeutics (LENZ) — Scientific Deep Dive for VIZZ (Aceclidine) 🔒 Paid

Articles open on Substack. Some are subscriber-only; those marked ★ Distilled Pro are for Distilled Pro members.